Ignite Creation Date:
2024-05-06 @ 12:49 AM
Last Modification Date:
2024-10-26 @ 10:55 AM
Study NCT ID:
NCT01667107
Status:
TERMINATED
Last Update Posted:
2018-10-09
First Post:
2012-08-14
Brief Title:
A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients MK-5592-105
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Pharmacokinetic Analysis of Posaconazole in the Plasma and Alveolar Compartment of Lung Transplant Recipients
Status:
TERMINATED
Status Verified Date:
2018-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study terminated due to an unfavorable risk-benefit analysis
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PAPAL
Brief Summary:
This single site study will examine plasma and alveolar compartment AC levels of posaconazole in cystic fibrosis CF and non-cystic fibrosis non-CF lung transplant recipients receiving routine post-operative anti-fungal prophylaxis Invasive fungal infection rates will be assessed following transplantation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2012-003140-68 | EUDRACT_NUMBER | None | None |